Abstract:Introduction Transformational advances have occurred in the management of haemophilia in the last decade leading to much better outcomes. However, a detailed and critical examination of its assessment and reporting show gaps in many aspects. These are discussed in this review. Methods The relevant literature related to different aspects of management of haemophilia was reviewed to identify gaps which need to be addressed. These include detection and diagnosis of haemophilia, documentation and reporting of joint bleeding, its management and methods of reporting in clinical trials and practice, aspects of personalizing care as well as access to therapeutic products and the need for and organization of comprehensive care. Results Current diagnostic approaches have more than doubled the identified number of persons with haemophilia (PWH) over the last 25 years but still constitute only ∼30% of the expected number. Joint bleeding is the primary indicator of disease severity and treatment efficacy, but there is lack of consistency and standardization in the way it is recorded and reported. Its continued use as an efficacy measure of modern treatments which maintain steady state factor levels or equivalence of >5% will lack sensitivity. The treatment of acute haemarthrosis has focussed on haemostasis and pain control, ignoring the role of inflammation in joint damage. Phenotypic heterogeneity of severe haemophilia has recognized clinical and laboratory variations based on haemostasis but not differences in local response to blood in the joint. At the organizational level, IU/capita provides a relevant measure of access to therapeutic products when the detection rate is ∼100% but is fallaciously low when detection rates are very low. With highly effective modern therapies for haemophilia and nearly no bleeding, the concept of comprehensive care team will need modifications. Conclusion As haemophilia care advances, a deeper dive is needed into the details of various aspects its management to ensure consistency and contemporary relevance.

Hemophilia management: optimizing treatment based on patient needs

The Evolution of Hemophilia Care: Clinical and Laboratory Advances, Opportunities, and Challenges

Transforming Hemophilia A Care: Insights into New Therapeutic Options

The Evolution of Hemophilia Pharmacological Treatments and Therapeutic Targets at the Turn of the Third Millennium

Benefits and risks of non‐factor therapies: Redefining haemophilia treatment goals in the era of new technologies

Shifting Paradigms and Arising Concerns in Severe Hemophilia A Treatment

Defining success in haemophilia care – Are we doing it right?

Hemophilia A: Strategies for Improving Long-Term Holistic Management, Adherence, and Quality of Life

Gene therapy for hemophilia: looking beyond factor expression

Recent Advances in Gene Therapy for Hemophilia: Projecting the Perspectives

Non-factor Therapies for Hemophilia: Achievements and Perspectives

Factor Replacement Treatment for Hemophilia A: Achievements and Perspectives

Future needs for continuing innovation in hemophilia: improving outcomes for individuals of all severities, including women and those in resource-constrained regions

How clinicians and persons with hemophilia may approach shared decision-making

Haemophilia in the era of novel therapies: Where do inhibitors feature in the new landscape?

The current challenges faced by people with hemophilia B

Nonsevere Hemophilia: The Need for a Renewed Focus and Improved Outcomes

Management of antithrombotic therapy for acute coronary syndromes and atrial fibrillation in patients with hemophilia

Optimizing long-term joint health in the treatment of hemophilia

Management of Hemophilia in Older Patients

Current and emerging Gene Therapies for Haemophilia A and B